609 Stock Chart & Stats
€3.93
>-€0.01(-0.18%)
At close: 4:00 PM EST
€3.93
>-€0.01(-0.18%)
Day’s Range― - ―
52-Week Range€1.26 - €4.92
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€82.39M
Enterprise Value€92.33M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding42,568,070
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Niche ApoA‑I Therapeutic PlatformABIONYX's specialized apoA‑I research platform targets inflammatory and infectious indications like sepsis. That focused scientific moat creates higher technical barriers to entry, supports a pipeline-driven model and, if clinical proof emerges, can deliver durable differentiated value across multiple high‑need therapeutic areas.
Lean Organizational StructureA small headcount implies a lean cost base and focused R&D teams, which can extend operational runway versus larger peers. Over the medium term this organizational efficiency supports disciplined cash deployment for clinical programs and makes the company more agile in reallocating resources as priorities shift.
Revenue Improved From Near‑zero BaselineRevenue rising from near‑zero suggests emerging commercial or partnership receipts and indicates some traction beyond purely preclinical R&D. While still small and volatile, this structural lift reduces absolute dependence on capital markets and provides a nascent foundation to build recurring or partnership-driven income.
Bears Say
Persistent Negative Cash FlowSustained operating and free cash outflows mean funding needs will persist absent major revenue or cost changes. Recurrent cash burn forces reliance on dilutive equity or debt financing, which erodes shareholder value or increases leverage, constraining long‑term R&D continuity and strategic flexibility.
Eroding Equity And Rising LeverageDeclining equity and a near doubling of debt-to-equity materially reduce balance‑sheet resilience. Elevated leverage limits the company's ability to raise inexpensive capital, raises refinancing risk, and may force unfavorable partnership terms or cutbacks that could delay clinical programs and harm long‑term value creation.
Weak, Volatile Revenue And Poor MarginsSharply deteriorating margins and very large operating losses relative to revenue indicate the business lacks scalable, margin-accretive revenue streams. Without structural margin recovery or new higher‑margin revenue sources, profitability appears distant, increasing dependence on external funding and heightening execution risk.
609 FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.26 and its highest was €4.92 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €82.39M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 60 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.091.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 42,568,070 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.841%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in DE:609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.